Welcome to our dedicated page for Eledon Pharmaceuticals SEC filings (Ticker: ELDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eledon Pharmaceuticals, Inc. (ELDN) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Eledon is a clinical stage biotechnology company focused on immune-modulating therapies built around the CD40 Ligand (CD40L) pathway, with its common stock listed on the Nasdaq Capital Market under the symbol ELDN, as noted in its Form 8-K filings.
Through this page, readers can review key documents such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe Eledon’s clinical programs for its lead investigational product tegoprubart, risk factors, and financial position. Current reports on Form 8-K provide more targeted updates, including material events related to clinical data disclosures, financing transactions and other significant corporate developments.
For example, an 8-K dated November 12, 2025 outlines an underwriting agreement for an underwritten public offering of common stock and pre-funded warrants, including the intended use of net proceeds to support continued clinical development and pipeline advancement. Other 8-K filings describe preliminary cash, cash equivalents and short-term investment balances, as well as press releases announcing Phase 2 BESTOW trial results and updated data from a Phase 1b kidney transplant study.
On Stock Titan, these filings are supplemented by AI-powered summaries that explain the main points of lengthy documents, helping users quickly understand topics such as capital raises, clinical trial disclosures and selected financial information. Real-time updates from EDGAR allow timely viewing of new ELDN filings, while access to forms like 10-K, 10-Q and 8-K supports deeper analysis of Eledon’s clinical-stage operations, financing activities and risk disclosures.
Eledon Pharmaceuticals, Inc. filed a shelf registration on that permits offers of up to $500,000,000 of common stock, preferred stock, debt securities, warrants and/or units. The filing also includes an at-the-market sales agreement to sell up to $75,000,000 of common stock through Guggenheim Securities.
The prospectus describes that sales under the sales agreement are at market prices or negotiated prices and that net proceeds will be used for working capital and general corporate purposes. The company reported 75,430,033 shares of common stock outstanding as of December 31, 2025, and the last reported sale price was $3.64 per share on April 30, 2026. The filing reiterates clinical-program details for tegoprubart and discloses that ALS development requires additional funding.
Eledon Pharmaceuticals is asking stockholders to approve three items at its 2026 annual meeting. Investors will vote on electing three Class III directors — David‑Alexandre C. Gros, M.D., Jan Hillson, M.D., and James Robinson — to terms running until the 2029 meeting.
They will also consider an amendment to increase authorized common shares from 300,000,000 to 450,000,000, which would give the company more capacity to issue equity in the future. A third proposal seeks ratification of Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026.
The proxy details governance practices, board committee structures and director independence, and outlines director and executive pay. As of the April 20, 2026 record date, 77,187,823 common shares were outstanding and entitled to vote at the June 18, 2026 in‑person meeting in Irvine, California.
BlackRock, Inc. reported beneficial ownership of 4,380,857 shares of Eledon Pharmaceuticals, Inc. common stock, equal to 5.8% of the class as of 03/31/2026. The Schedule 13G shows BlackRock holds sole dispositive power for 4,380,857 shares and sole voting power for 4,324,348 shares. The filing notes that various persons may have rights to dividends or sale proceeds and that no single outside person holds more than 5% of the class.
Eledon Pharmaceuticals will hold its 2026 Annual Meeting of Stockholders on June 18, 2026 at its Irvine, California office to elect three Class III directors, seek stockholder approval to increase authorized common shares from 300,000,000 to 450,000,000, and ratify Deloitte & Touche LLP as auditor. The Board set the record date as April 20, 2026. Proxy materials and the 2025 Annual Report are available at proxydocs.com/ELDN. The Proxy Statement describes director nominees, governance policies, committee composition, non-employee director pay, named executive officer compensation, related-party financings involving certain institutional holders, and procedures for voting in person, by phone, internet, or mail.
Eledon Pharmaceuticals Inc amendment to a Schedule 13G/A shows The Vanguard Group reports 0 shares beneficially owned, representing 0% of the common stock. The filing explains an internal realignment on January 12, 2026 that led certain Vanguard subsidiaries to report separately.
Eledon Pharmaceuticals reported a 2025 net loss of $45.6 million, wider than $36.2 million in 2024, as it increased investment in its lead antibody tegoprubart, mainly for kidney transplant studies. Research and development spending rose to $66.3 million, while general and administrative costs declined to $17.0 million.
The company ended 2025 with cash, cash equivalents and short-term investments of $133.3 million and working capital of $117.3 million, and expects this to fund operations for at least 12 months. Management states additional capital will be needed to advance programs beyond that period and to continue clinical development of tegoprubart for ALS.
Eledon Pharmaceuticals reported fourth quarter and full year 2025 results and highlighted progress for its lead antibody tegoprubart in multiple transplant settings. The FDA granted Orphan Drug designation for preventing allograft rejection in liver transplantation, adding to prior orphan designations in islet cell transplantation and ALS.
In a Phase 1b kidney transplant extension study, eight patients followed for 24 months had no biopsy-proven acute rejection, graft loss, death, new-onset diabetes, or de novo donor-specific antibodies, while mean eGFR rose from 67.0 to 74.2 mL/min/1.73 m². In a UChicago islet transplant trial for type 1 diabetes, all 10 evaluable patients achieved insulin independence with most recent HbA1c below 6.0% and a mean of about 5.35%, with no rejection or typical tacrolimus-related toxicities.
For 2025, research and development expenses were $66.3 million versus $52.0 million in 2024, and general and administrative expenses were $17.0 million versus $18.6 million. Net loss was $45.6 million, or $0.52 per common share, compared to a $36.2 million loss, or $0.66 per share, in 2024. Results included non-cash gains from changes in warrant liabilities of $33.4 million in 2025 and $30.9 million in 2024.
Eledon Pharmaceuticals, Inc. received an amended Schedule 13G from RA Capital Management and related reporting persons regarding its common stock. As of December 31, 2025, RA Capital Management, Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. each report beneficial ownership of 0 shares and 0.0% of the common stock, with no sole or shared voting or dispositive power. The filers also certify that the securities referenced were not acquired and are not held for the purpose of changing or influencing control of Eledon Pharmaceuticals.
Coastlands-affiliated funds and Matthew D. Perry report minority ownership in Eledon Pharmaceuticals, Inc. on an amended Schedule 13G. Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC and Perry collectively report beneficial ownership of 3,937,826 shares of Eledon common stock, representing 4.99% of the class.
This position includes 450,000 shares held directly by Coastlands Capital LP and 3,487,826 shares issuable upon exercise of pre-funded warrants, all subject to a 4.99% beneficial ownership limitation. Perry’s reported beneficial ownership of 3,908,467 shares includes additional stock held through a trust. The filers state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Eledon.